Characterization of Response to Ipilimumab and Nivolumab in patients with Melanoma

Characterization of Response to Ipilimumab and Nivolumab in patients with Melanoma Prof. Raanan Berger Back to your profile View as PDF Research Inquiry What are the clinical and genomics characterization of durable responses to Ipilimumab + Nivolumab in Melanoma? Key Points Among the factors that were found and may predict response to immunotherapy, specifically Ipilimumab, […]

Durable responses to Ipilimumab + Nivolumab

Durable responses to Ipilimumab + Nivolumab Prof. Raanan Berger Back to your profile View as PDF Research Inquiry What are the clinical and genomics characterization of durable responses to Ipilimumab + Nivolumab in Renal Cell Carcinoma? Another report regarding the genomic and clinical characteristics of durable responses to Ipilimumab + Nivolumab in Melanoma will be […]

Prostate cancer with peritoneal spread

Prof. Raanan Berger Prostate cancer with peritoneal spread   |  15.07.22 Back to your profile  Conclusion Peritoneal carcinomatosis is a rare site of metastatic  i prostate cancer and the etiology remains poorly understood. Even though, as we learn from the published data, one of the etiologies might be prostatectomy by surgery. Nevertheless, there are previously […]

Fibrolamellar HCC

Prof. Raanan Berger Immunotherapy for Fibrolamellar Hepatocellular Carcinoma  |  14.07.22 Back to your profile  Research Inquiry What is the present experience with immunotherapy for Fibrolamellar Hepatocellular Carcinoma (FL-HCC, FLC)? Meta Medical Findings Overall, controlled trials and systematic reports evaluating the efficacy of immunotherapy in FL-HCC are lacking, and only a few case reports and retrospective […]